Kisspeptin[KISS1 peptides; kisspeptin-54 and kisspeptin-10]
Compound snapshot
Class
Research peptide
FDA approved
No
Clinical development
Phase 1
Last reviewed
September 2026
Research areas
Cognition / Mood / Neuroprotection
Regulatory status
Investigational — not approved
Internet attention
Moderate
Registry query
Kisspeptin
A family of natural neuropeptides encoded by the KISS1 gene. Kisspeptin is a master upstream signal for human reproductive hormone release and has been studied in infertility and hypothalamic reproductive disorders.
Reality check — what we actually know
Supported by human evidence
- No adequately powered randomised human trials establish the outcomes this compound is marketed for.
Animal research only
- Reliably stimulates LH and other reproductive hormones in controlled human physiology studies
- Triggered egg maturation in fertility-treatment research while being studied as an alternative to conventional triggers
- Produced hormonal responses in studies of hypothalamic amenorrhoea and hypogonadism
Mechanistically plausible
- Activates KISS1R on hypothalamic neurons, stimulating pulsatile gonadotropin-releasing hormone. That signal drives pituitary LH and FSH release and then ovarian or testicular sex-hormone production.
Common internet claims
- Online discussion frequently presents Kisspeptin as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for Kisspeptin, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Activates KISS1R on hypothalamic neurons, stimulating pulsatile gonadotropin-releasing hormone. That signal drives pituitary LH and FSH release and then ovarian or testicular sex-hormone production.
- Reliably stimulates LH and other reproductive hormones in controlled human physiology studies
- Triggered egg maturation in fertility-treatment research while being studied as an alternative to conventional triggers
- Produced hormonal responses in studies of hypothalamic amenorrhoea and hypogonadism
- Pulsatile delivery is being investigated because continuous exposure can rapidly lose effect
Strength of the evidence: Moderate early human evidence from mechanistic and Phase 1–2 studies, but no major regulator has approved kisspeptin as a medicine. Fertility outcomes and long-term safety still need larger trials.
Safety and known cautions
Hormonal responses vary by sex, menstrual-cycle stage and delivery pattern. Repeated continuous exposure can cause tachyphylaxis, or diminishing response. Fertility and sex-hormone treatment requires specialist monitoring.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1Current
- Phase 2
- Phase 3
- Regulatory review
- Approved